万达生物制药 VNDA 深 沪
已收盘 10-02 16:00:00 美东时间
4.63
-0.180
-3.74%
华盛通- 最 高4.85
- 今 开4.85
- 成交量 144.90万股
- 最 低 4.565
- 昨 收 4.81
- 总市值 2.80亿
- 52周最高 9.94
- 市盈率 静 --
- 换手率 2.40%
- 52周最低 4.27
- 委 比 -88.03%
- 总股本 6046.27万
- 历史最高 33.44
- 量 比 0.85
- 振 幅 5.93%
- 历史最低 2.92
- 每 手 1
- 风险率 1.17%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting
WASHINGTON, Oct. 2, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced participation at the European Academy of Dermatology and Venereology (EADV) Annual Meeting,...
10-02 21:06
Vanda Eyes First FDA-Approved Delayed Sleep-Wake Disorder Drug
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Tuesday shared topline results from a pivotal Phase 3 trial evaluating HETLIOZ (tasimelteon) 20 mg in adults with Delayed Sleep-Wake Phase Disorder (DSWPD). The company plans to present these results to the U.S. Food and Drug Administration and submit a su...
09-30 21:10
美股大行评级 | 汽车地带绩后遭10家机构降目标价！最低看至3000美元；美光、微软、Meta齐获看多
今日重点评级关注：Leerink Partners：维持塞德斯医疗"跑赢大市"评级，目标价从70美元升至88美元；HC Wainwright & Co.：维持TriSalus Life Sciences"买入"评级，目标价从11美元升至12美元
09-24 16:10
Oppenheimer Initiates Coverage On Vanda Pharmaceuticals with Outperform Rating, Announces Price Target of $10
Oppenheimer analyst Les Sulewski initiates coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) with a Outperform rating and announces Price Target of $10.
09-23 20:11
NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
WASHINGTON, Aug. 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the NEREUS™ branded No. 47 entry from Rahal Letterman Lanigan Racing, driven by Mick ...
08-23 03:16
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
HC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Lowers Price Target to $20
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and lowers the price target from $21 to $20.
08-10 18:23
Vanda Pharma Says FDA Grants Rare Pediatric Disease Designation To VCA-894A For Treatment Of Charcot-Marie-Tooth Disease, Axonal, Type 2S
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to VCA-894A, Vanda's investigational antisense oligonucleotide therapy for the treatment of Charcot-Marie-Tooth disease, axonal, type 2S (C...
07-08 04:33
Vanda Pharmaceuticals Receives Japanese Orphan Drug Designation For Imsidolimab In Generalized Pustular Psoriasis
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to imsidolimab, a high‑affinity humanized immunoglobulin G4
05-27 19:11
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
